Boston Scientific (NYSE: BSX) EVP reports stock awards and tax share offsets

Rhea-AI Filing Summary

Boston Scientific EVP, GC and Corporate Secretary Vance R. Brown reported multiple equity compensation transactions. On February 13–16, 2026, he acquired Boston Scientific common stock through the exercise and conversion of restricted stock units and performance share units, and through grants and awards, all at a stated price of $0.00 per share.

On these dates, shares of common stock were also disposed of at $74.73 per share to satisfy tax liabilities by delivering securities. Footnotes explain that performance share units granted on February 14, 2023 vested based on three-year total shareholder return and organic net sales performance through December 31, 2025, subject to a three-year service period satisfied on February 13, 2026. Each restricted stock unit represents a commitment to issue one share in four equal annual installments beginning on specified anniversaries of the grant dates.

Insider Trade Summary

4,808 shares exercised/converted

Mixed 11 txns

Insider Brown Vance R

Role EVP, GC and Corp. Secretary

Type	Security	Shares	Price	Value
Exercise	Restricted Stock Units	1,839	$0.00	--
Exercise	Common Stock	1,839	$0.00	--
Tax Withholding	Common Stock	890	$74.73	$67K
Exercise	Restricted Stock Units	1,851	$0.00	--
Exercise	Common Stock	1,851	$0.00	--
Tax Withholding	Common Stock	895	$74.73	$67K
Exercise	Restricted Stock Units	1,118	$0.00	--
Grant/Award	Common Stock	14,804	$0.00	--
Grant/Award	Common Stock	14,804	$0.00	--
Exercise	Common Stock	1,118	$0.00	--
Tax Withholding	Common Stock	12,792	$74.73	$956K

Holdings After Transaction: Restricted Stock Units — 0 shares (Direct); Common Stock — 55,134 shares (Direct)

Footnotes (1)

1. On February 14, 2023, the reporting person was awarded a target number of performance share units under the Company's 2023 Total Shareholder Return Performance Share Program, with the actual number to be earned by the reporting person to be based on the Company's total shareholder return performance percentile relative to that of the other companies in the S&P 500 Health Care Index over the three-year performance cycle comprising the three-year period ended December 31, 2025 and subject to the completion of the concurrent three-year individual service period. On February 13, 2026, the number of performance share units as to which the performance criteria had been satisfied was determined and the individual service period was satisfied. On February 14, 2023, the reporting person was awarded a target number of performance share units under the Company's 2023 Organic Net Sales Performance Share Program, with the actual number to be earned by the reporting person to be based on the Company's organic net sales performance measured against its financial plan over the three-year performance cycle comprising the three-year period ended December 31, 2025 and subject to the completion of the concurrent three-year individual service period. On February 13, 2026, the number of performance share units as to which the performance criteria had been satisfied was determined and the individual service period was satisfied. Each restricted stock unit represents the Company's commitment to issue one share of Boston Scientific common stock. Shares of common stock will be issued to the reporting person in four equal annual installments beginning on February 13, 2026, the first anniversary of the date of grant. Shares of common stock will be issued to the reporting person in four equal annual installments beginning on February 14, 2024, the first anniversary of the date of grant. Shares of common stock will be issued to the reporting person in four equal annual installments beginning on February 16, 2023, the first anniversary of the date of grant.

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Brown Vance R

(Last) (First) (Middle)

300 BOSTON SCIENTIFIC WAY

(Street)

MARLBOROUGH MA 01752-1234

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
BOSTON SCIENTIFIC CORP [ BSX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	EVP, GC and Corp. Secretary

3. Date of Earliest Transaction (Month/Day/Year)
02/13/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	02/13/2026		A(1)		14,804	A	$0.0000	49,209	D
Common Stock	02/13/2026		A(2)		14,804	A	$0.0000	64,013	D
Common Stock	02/13/2026		M		1,118	A	$0.0000(3)	65,131	D
Common Stock	02/13/2026		F		12,792	D	$74.73	52,339	D
Common Stock	02/14/2026		M		1,851	A	$0.0000(3)	54,190	D
Common Stock	02/14/2026		F		895	D	$74.73	53,295	D
Common Stock	02/16/2026		M		1,839	A	$0.0000(3)	55,134	D
Common Stock	02/16/2026		F		890	D	$74.73	54,244	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Restricted Stock Units	(3)	02/13/2026		M			1,118	(4)	02/13/2029(4)	Common Stock	1,118	$0.0000	3,357	D
Restricted Stock Units	(3)	02/14/2026		M			1,851	(5)	02/14/2027(5)	Common Stock	1,851	$0.0000	1,851	D
Restricted Stock Units	(3)	02/16/2026		M			1,839	(6)	02/16/2026(6)	Common Stock	1,839	$0.0000	0.0000	D

Explanation of Responses:

1. On February 14, 2023, the reporting person was awarded a target number of performance share units under the Company's 2023 Total Shareholder Return Performance Share Program, with the actual number to be earned by the reporting person to be based on the Company's total shareholder return performance percentile relative to that of the other companies in the S&P 500 Health Care Index over the three-year performance cycle comprising the three-year period ended December 31, 2025 and subject to the completion of the concurrent three-year individual service period. On February 13, 2026, the number of performance share units as to which the performance criteria had been satisfied was determined and the individual service period was satisfied.

2. On February 14, 2023, the reporting person was awarded a target number of performance share units under the Company's 2023 Organic Net Sales Performance Share Program, with the actual number to be earned by the reporting person to be based on the Company's organic net sales performance measured against its financial plan over the three-year performance cycle comprising the three-year period ended December 31, 2025 and subject to the completion of the concurrent three-year individual service period. On February 13, 2026, the number of performance share units as to which the performance criteria had been satisfied was determined and the individual service period was satisfied.

3. Each restricted stock unit represents the Company's commitment to issue one share of Boston Scientific common stock.

4. Shares of common stock will be issued to the reporting person in four equal annual installments beginning on February 13, 2026, the first anniversary of the date of grant.

5. Shares of common stock will be issued to the reporting person in four equal annual installments beginning on February 14, 2024, the first anniversary of the date of grant.

6. Shares of common stock will be issued to the reporting person in four equal annual installments beginning on February 16, 2023, the first anniversary of the date of grant.

	/s/ Susan Thompson, Attorney-in-Fact	02/18/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What did Boston Scientific (BSX) executive Vance R. Brown report in this Form 4 filing?

Vance R. Brown reported equity compensation activity, including exercises and conversions of restricted stock units and performance share units into common stock, plus stock grants and awards. Some shares were also delivered back to cover tax liabilities at a stated price per share.

Were any Boston Scientific (BSX) shares sold on the open market in this Form 4?

The filing shows share dispositions coded as tax-withholding transactions, not open market sales. Shares of common stock were delivered at $74.73 per share to pay exercise price or tax liabilities, according to the transaction code description provided.

What performance share programs affected Vance R. Brown’s Boston Scientific (BSX) awards?

Brown’s awards came from 2023 performance share programs tied to total shareholder return and organic net sales. Both measured performance over the three-year period ended December 31, 2025, and also required completion of a concurrent three-year individual service period.

When were the Boston Scientific (BSX) performance criteria and service conditions satisfied for Brown’s awards?

The filing states that on February 13, 2026, the number of performance share units meeting performance criteria was determined and the three-year individual service period was satisfied. This applied to both the total shareholder return and organic net sales performance share programs granted in 2023.

How do Boston Scientific (BSX) restricted stock units reported by Brown convert into common shares?

Each restricted stock unit represents a commitment to issue one share of Boston Scientific common stock. According to the footnotes, shares will be issued to Brown in four equal annual installments beginning on specified anniversaries of the respective grant dates.

What price per share is associated with the tax-withholding dispositions in this Boston Scientific (BSX) Form 4?

The tax-withholding dispositions of common stock are reported at a transaction price of $74.73 per share. These transactions are described as payments of exercise price or tax liability by delivering securities rather than as open market sales.